denkapparat Operations’s Biogen BIIB Stock Holding History

denkapparat Operations’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.37M	Hold	6,338	–	–	0.45%	57
2026 Q1	$1.16M	Hold	6,338	–	–	0.48%	58
2025 Q4	$1.12M	Hold	6,338	–	–	0.61%	32
2025 Q3	$888K	Buy	6,338 +2,098	+49%	+$284K	0.57%	46
2025 Q2	$533K	Buy	4,240 +1,000	+31%	+$125K	0.43%	85
2025 Q1	$443K	Buy	3,240 +1,620	+100%	+$232K	0.47%	86
2024 Q4	$248K	Buy	+1,620	New	+$273K	0.37%	119

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

denkapparat Operations's BIIB Position: Q2 2026 in Review

denkapparat Operations held its Biogen (BIIB) position steady in Q2 2026 at 6,338 shares worth $1.37M. The position accounts for 0.45% of the portfolio, ranked #57.

denkapparat Operations first reported a position in BIIB in Q4 2024 and has held it in 7 quarters since. 1,046 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

denkapparat Operations held 6,338 shares of Biogen worth $1.37M as of Q2 2026.
denkapparat Operations left its Biogen share count unchanged in Q2 2026.
Biogen made up 0.45% of denkapparat Operations's portfolio in Q2 2026, its #57 holding.
denkapparat Operations first reported a position in Biogen in Q4 2024 and has held it in 7 quarters since.
1,046 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on denkapparat Operations's 13F filing for Q2 2026, filed 6 Aug 2026.